Barinthus Biotherapeutics (STU:2AB) GF Value Rank: 4 (As of Jul. 01, 2026) — Near Median


STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.57
GF Value €0.96
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics GF Value Rank?

Barinthus Biotherapeutics STU:2AB -0.88% 14 GF Value Rank is 4 as of Jul. 01, 2026, which is at its 10-year median of 4.00. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.96. The stock has 1 warning sign investors should review.

Barinthus Biotherapeutics has the GF Value Rank of 4.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Barinthus Biotherapeutics GF Value Rank Related Terms


STU:2AB vs VTGN, PSTV, PVCT: GF Value Rank Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Barinthus Biotherapeutics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's GF Value Rank falls into.


STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 4 mean?
Barinthus Biotherapeutics (STU:2AB) has a GF Value Rank of 4 as of Jul. 01, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Barinthus Biotherapeutics and its competitors. This is near median its historical median of 4.00. Over the past decade, Barinthus Biotherapeutics' GF Value Rank has ranged from 4.00 to 9.00.
Is Barinthus Biotherapeutics' GF Value Rank too high?
Barinthus Biotherapeutics' current GF Value Rank of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' GF Value Rank compare to VTGN and PSTV?
Barinthus Biotherapeutics' GF Value Rank of 4 can be compared against companies in the Biotechnology industry. Historically, Barinthus Biotherapeutics' own GF Value Rank has ranged from 4.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current GF Value Rank is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current GF Value Rank of 4. The stock's GF Value™ is €0.96, compared to a current price of €0.57 — trading 41.1% below its estimated fair value. The current GF Value Rank is 4, which is near median its 10-year median of 4.00. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current GF Value Rank is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.57 is trading 41.1% below its estimated GF Value™ of €0.96.

Key valuation signals for STU:2AB:

  • GF Value Rank: 4 (near median its 10-year median of 4.00)
  • GF Value™: €0.96 vs. price of €0.57 (41.1% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.57
Price
€0.96
GF Value